| 朱祎静,张 仪,尤良顺.嵌合抗原受体T细胞治疗淋巴瘤的现状及展望[J].中国肿瘤,2020,29(10):787-791. |
| 嵌合抗原受体T细胞治疗淋巴瘤的现状及展望 |
| Progress of Chimeric Antigen Receptor T-cell Immunotherapy(CART) in Treatment of Lymphoma |
| 中文关键词 修订日期：2020-06-30 |
| DOI：10.11735/j.issn.1004-0242.2020.10.A011 |
|
 |
| 中文关键词: CART治疗 B细胞淋巴瘤 霍奇金淋巴瘤 免疫治疗 |
| 英文关键词:chimeric antigen receptor T cell therapy B-cell lymphoma Hodgkin lymphoma immunotherapy |
| 基金项目:浙江省卫健委省部共建项目（WKJ-ZJ-1709） |
|
| 摘要点击次数: 1302 |
| 全文下载次数: 217 |
| 中文摘要: |
| 摘 要：近年来，随着免疫治疗和基因工程的兴起，嵌合型抗原受体T细胞疗法（chimeric antigen receptor T-cell immunotherapy，CART）由于其安全有效、患者耐受性好的特点，为复发/难治的淋巴瘤患者带来了新的希望。本文综述了CART的原理及免疫机制、CART在淋巴瘤中的应用、CART治疗面临的问题及CART治疗淋巴瘤的未来及展望。 |
| 英文摘要: |
| Abstract：In recent years，with the development of immunotherapy and genetic engineering，chimeric antigen receptor T cell therapy（CART） has brought new hope to patients with relapsed/refractory lymphoma due to its safe and effective characteristics and good patient tolerance. This article reviews the principles and immune mechanisms of CART therapy，the application of CART in lymphoma，the problems faced by CART，and the future and prospect of CART therapy for lymphoma. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |